Amundi’s Tarsus Pharmaceuticals TARS Stock Holding History

Amundi’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10	Closed	-$496	–	2126
2025 Q1	$496	Sell	10 -37	-79%	-$1.83K	﹤0.01%	2127
2024 Q4	$2.6K	Buy	+47	New	+$2.13K	﹤0.01%	1974

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Amundi's TARS Position: Q2 2025 in Review

Amundi sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 10 shares — an estimated $496 sold.

Amundi first reported a position in TARS in Q4 2024 and held it in 2 quarters. The position peaked at $2.6K in Q4 2024. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

Amundi reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Amundi sold 10 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $496.
Amundi first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Amundi's Tarsus Pharmaceuticals position peaked at $2.6K in Q4 2024.
205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.